Imagine you have just finalized a deep-dive valuation model for a mid-cap IT services firm. You arrive at a target price that suggests a 12% upside over the next year, and your instinct is to slap an ‘Overweight’ rating on the report. However, your supervisor stops you, pointing out that the Nifty IT Index is expected to climb by 18% during the same period.
By ignoring the broader market expectations, you risk recommending a stock that, while technically profitable in absolute terms, is a wealth destroyer in relative terms. This scenario highlights the critical divide between absolute return expectations and relative performance benchmarks.
An absolute return approach focuses purely on whether a stock will increase in price, regardless of the broader market environment. This perspective is often intuitive for retail investors, as it measures wealth growth against a zero-base or a risk-free rate. In contrast, institutional research mandates typically demand a relative return framework, where the performance of a stock is measured against a relevant benchmark index.
When you label a stock as ‘Overweight,’ you are signaling that your conviction exceeds the stock’s current weighting in the benchmark index, essentially betting that it will outperform the sector or the broader market.
Why does this distinction matter for your NISM-XV examination and professional practice? Failing to benchmark correctly can lead to misaligned portfolio construction. Consider an investor managing a large-cap oriented fund; if you recommend an ‘Overweight’ position in a volatile small-cap stock without clarifying its relative benchmark, you are providing incomplete risk-adjusted guidance. Your report must explicitly define whether your return target is compared to the Nifty 50, a sector-specific index, or a custom peer-group composite. This clarity allows portfolio managers to understand the ‘active share’ component of your recommendation.
Take the example of two pharmaceutical companies: one is a stable blue-chip firm, and the other is a high-growth biosimilar entrant. A 10% expected return might warrant an ‘Underweight’ rating for the biosimilar firm if its beta is high and the index is rallying, while the exact same return could justify an ‘Overweight’ rating for the blue-chip firm in a defensive, sideways market.
Your role as an analyst is to ensure that your recommendation explicitly addresses this gap between raw price appreciation and the opportunity cost of not investing in the benchmark itself.1
Nuance
Check Your Understanding
An analyst expects a stock to provide an absolute return of 5% over the next 12 months. If the relevant sector benchmark is expected to decline by 3% over the same period, how should this expectation be interpreted in a professional research context?
Which of the following best describes the fundamental purpose of utilizing a relative return benchmark in a research report?
This is a companion read for Section 13.1 — Qualities of a Good Research Report from PASS Research Analyst Certification Examination by Akhilesh Gururani, available on Amazon Kindle.
Copyright © 2026 Akhilesh Gururani. All rights reserved.
-
Active share measures the percentage of a portfolio that differs from its benchmark index, reflecting the manager’s conviction. ↩︎